StockData

Jupiter Neurosciences vs Kiora Pharmaceuticals

JUNS and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JUNS and KPRX compare

Kiora Pharmaceuticals is the larger company, worth 3.3 times as much as Jupiter Neurosciences ($4.3M against $1.3M).

Kiora Pharmaceuticals scores higher on the StockData Score (7 against 0 for Jupiter Neurosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJUNSKPRX
Size and price
Market cap$1.3M$4.3M
Share price$1.70$0.982
Change, 1 year−98.3%−55.3%
Change, 5 years–−99.8%
Beta (5Y)−0.181.59
Employees53,500
StockData Score
Total score07 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score05 (better)
Dividend score00
Valuation
P/B–0.3×
FCF yield–−198%
Profitability
Return on equity−1889%−56.4% (better)
Return on invested capital–−1374%
Financial health
Debt / equity–0.00
Interest coverage−36.0×–
Current ratio0.668.97 (better)
Altman Z-score−23.63−9.80 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions2.2%25.0%
Held by insiders–3.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.